Dr. Domchek on the MEDIOLA Trial in Breast Cancer

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses the MEDIOLA trial in breast cancer.

During the 2017 San Antonio Breast Cancer Symposium, the results of the first 25 patients with BRCA1/2-mutated metastatic breast cancer treated with olaparib (Lynparza) and durvalumab (Imfinzi) from the MEDIOLA trial were presented.

Results showed an 80% clinical benefit rate at 12 weeks, suggesting that this is an active combination in this population. The impact of durvalumab is still unknown, says Domchek, as olaparib has shown benefit as a single-agent in this population.